Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 1
1985 3
1986 4
1987 3
1988 5
1989 13
1990 18
1991 17
1992 19
1993 21
1994 25
1995 25
1996 51
1997 48
1998 40
1999 43
2000 32
2001 39
2002 40
2003 41
2004 29
2005 42
2006 38
2007 39
2008 44
2009 40
2010 47
2011 55
2012 47
2013 42
2014 42
2015 36
2016 27
2017 13
2018 14
2019 18
2020 10
2021 11
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

1,019 results
Results by year
Filters applied: . Clear all
Page 1
Cancer-Cell-Intrinsic cGAS Expression Mediates Tumor Immunogenicity.
Schadt L, Sparano C, Schweiger NA, Silina K, Cecconi V, Lucchiari G, Yagita H, Guggisberg E, Saba S, Nascakova Z, Barchet W, van den Broek M. Schadt L, et al. Among authors: yagita h. Cell Rep. 2019 Oct 29;29(5):1236-1248.e7. doi: 10.1016/j.celrep.2019.09.065. Cell Rep. 2019. PMID: 31665636 Free article.
Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance.
Muraoka D, Seo N, Hayashi T, Tahara Y, Fujii K, Tawara I, Miyahara Y, Okamori K, Yagita H, Imoto S, Yamaguchi R, Komura M, Miyano S, Goto M, Sawada SI, Asai A, Ikeda H, Akiyoshi K, Harada N, Shiku H. Muraoka D, et al. Among authors: yagita h. J Clin Invest. 2019 Mar 1;129(3):1278-1294. doi: 10.1172/JCI97642. Epub 2019 Feb 11. J Clin Invest. 2019. PMID: 30628894 Free PMC article.
Retraction. Resistance to Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis and constitutive expression of Apo2L/TRAIL in human T-cell leukemia virus type 1-infected T-cell lines. Journal of Virology, Volume 79, no. 3, p. 1367-78, 2005.
Matsuda T, Almasan A, Tomita M, Uchihara JN, Masuda M, Ohshiro K, Takasu N, Yagita H, Ohta T, Mori N. Matsuda T, et al. Among authors: yagita h. J Virol. 2011 Feb;85(3):1416. doi: 10.1128/JVI.02070-10. J Virol. 2011. PMID: 21228250 Free PMC article. No abstract available.
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet AL, Latreche S, Bergaya S, Benhamouda N, Tanchot C, Stockmann C, Combe P, Berger A, Zinzindohoue F, Yagita H, Tartour E, Taieb J, Terme M. Voron T, et al. Among authors: yagita h. J Exp Med. 2015 Feb 9;212(2):139-48. doi: 10.1084/jem.20140559. Epub 2015 Jan 19. J Exp Med. 2015. PMID: 25601652 Free PMC article.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA. Simpson TR, et al. Among authors: yagita h. J Exp Med. 2013 Aug 26;210(9):1695-710. doi: 10.1084/jem.20130579. Epub 2013 Jul 29. J Exp Med. 2013. PMID: 23897981 Free PMC article.
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1.
Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, Fujioka Y, Ohba Y, Gorman JV, Colgan JD, Hirashima M, Uede T, Takaoka A, Yagita H, Jinushi M. Chiba S, et al. Among authors: yagita h. Nat Immunol. 2012 Sep;13(9):832-42. doi: 10.1038/ni.2376. Epub 2012 Jul 29. Nat Immunol. 2012. PMID: 22842346 Free PMC article.
Oral immunotherapy for allergic conjunctivitis.
Ishida W, Fukuda K, Harada Y, Yagita H, Fukushima A. Ishida W, et al. Among authors: yagita h. Cornea. 2014 Nov;33 Suppl 11:S32-6. doi: 10.1097/ICO.0000000000000241. Cornea. 2014. PMID: 25289722 Review.
1,019 results